Akathisia Medications
For antipsychotic-induced akathisia, first-line treatment should be beta-blockers (propranolol 10-30 mg two to three times daily), benzodiazepines (lorazepam 0.5-1.25 mg), or mirtazapine (15 mg), with beta-blockers and benzodiazepines showing the strongest evidence for efficacy. 1, 2
Treatment Algorithm
Step 1: Antipsychotic Dose Adjustment
- Reduce the antipsychotic dose if clinically feasible without worsening psychotic symptoms 3, 4, 2
- Discontinue antipsychotic polypharmacy if present 2
- Consider switching to an antipsychotic with lower akathisia liability (quetiapine or olanzapine) 5, 2
Step 2: First-Line Pharmacological Treatment
If dose reduction is insufficient or not possible, choose from these evidence-based options:
Beta-blockers (Preferred):
- Propranolol 10-30 mg two to three times daily 5, 2
- Ranked highest in comparative efficacy (P-score 0.8186 after benzodiazepines) 1
- Contraindicated in patients with asthma, heart block, or significant bradycardia
Benzodiazepines:
- Lorazepam 0.5-1.25 mg (can be sublingual) 6, 2, 7
- Clonazepam as alternative 2
- Highest P-score ranking (0.8186) in network meta-analysis 1
- Caution: respiratory depression, confusion, ataxia in elderly 6
Mirtazapine (NaSSA):
- 15 mg daily 5, 2, 8
- Particularly effective for treatment-resistant akathisia 8
- Acts as 5HT2A antagonist 2, 9
Step 3: Alternative Agents
If first-line treatments fail or are contraindicated:
Anticholinergics:
- Biperiden 2-4 mg/day 7
- Trihexyphenidyl 5 mg orally 9, 7
- Not consistently helpful for akathisia specifically 3, but may be tried
Other 5HT2A Antagonists:
Step 4: Combination Therapy
- If monotherapy inadequate, combine beta-blocker with benzodiazepine 2
- Consider adding mirtazapine to existing regimen for refractory cases 8
Critical Clinical Considerations
Diagnostic Pitfalls:
- Akathisia is frequently misinterpreted as psychotic agitation or anxiety, leading to inappropriate antipsychotic dose increases 3
- Use validated assessment scales (Barnes Akathisia Rating Scale) before and during treatment 2, 8
- Distinguish from other movement disorders: dystonia, parkinsonism, tardive dyskinesia 3
Risk Factors:
- High-potency antipsychotics (haloperidol) carry higher risk 3, 10
- High doses or antipsychotic polypharmacy 10
- Bipolar depression, substance abuse comorbidity 10
- Second-generation antipsychotics (risperidone, aripiprazole) can also cause akathisia, though less frequently than first-generation agents 11, 10
Treatment Duration:
- Evidence for duration of adjuvant medication use is limited 2
- Reassess need for antiparkinsonian agents after acute phase or if antipsychotic dose is lowered 3
- Cautious prescribing warranted given evidence limitations 2
Evidence Quality Note
The 2024 network meta-analysis 1 provides the most recent high-quality evidence, demonstrating significant efficacy for benzodiazepines (SMD vs placebo), beta-blockers, and NaSSA (mirtazapine). The 2018 Canadian guideline 2 offers the most comprehensive systematic approach to treatment. Notably, anticholinergics showed no significant difference from placebo in the meta-analysis 1, despite their common use, while beta-blockers were previously found ineffective in one older study 7—this discrepancy highlights the importance of the most recent evidence.
Avoid benztropine or trihexyphenidyl specifically for akathisia as recommended in older guidelines 11, as they are not consistently effective for this particular extrapyramidal symptom 3.